Sign in
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
Journal article   Peer reviewed

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor

Wenxian Wang, Qian Wang, Chunwei Xu, Ziming Li, Zhengbo Song, Yongchang Zhang, Xiuyu Cai, Shirong Zhang, Bin Lian, Wen Li, …
Thoracic cancer, Vol.13(23), pp.3420-3430
12/2022
PMID: 36268845

Abstract

Antineoplastic Agents, Immunological - therapeutic use China Consensus Humans Immune Checkpoint Inhibitors - adverse effects Lung Neoplasms - drug therapy Pneumonia - chemically induced Pneumonia - diagnosis Pneumonia - drug therapy
Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in-depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP.

Metrics

1 Record Views

Details